CVS restores Zepbound coverage, adds Eli Lilly’s obesity pill Foundayo
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on…
The Deadly Venom Behind Ozempic—and Why the Miracle Drug Should Have Never Worked
When scientists first discovered the insulin secretion effects of gut hormone GLP-1 in the 1980s, it seemed like…
Scientists Discover Common Medications May Secretly Alter Your Gut for Years
Researchers found that many commonly prescribed drugs, not just antibiotics, were linked to long-lasting microbial changes that could…
What to expect at Trump Jr.-backed ‘Steroid Olympics’ this Sunday
A new sports competition featuring Olympic medalists will take place in Las Vegas on Sunday. The twist? The…
Lilly’s Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
In ATTAIN-MAINTAIN, participants who transitioned from a maximum tolerated dose (MTD) of Wegovy (semaglutide) to Foundayo maintained all…
When pills change shapes and colors, confusion is a side effect
At the ripe old age of 73, I take six drugs — four prescription and two over-the-counter pills…
Creatv Bio Opens CLIA-Certified Laboratory to Support Oncology Drug Development
MONMOUTH JUNCTION, N.J., May 13, 2026 /PRNewswire/ — Creatv Bio, a Division of Creatv MicroTech, Inc. (“Creatv”), a…
Hantavirus cases spark surge in pharma, biotech stocks — here’s why
ILLUSTRATION of hantavirus testing concept with laboratory tubes containing cotton swabs and HANTAVIRUS labels photographed in front of…
Medicare spending far less than expected on new Alzheimer’s drugs
Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences…
Roche to acquire startup PathAI for $750 million upfront
Roche has signed a deal to pay $750 million upfront for Boston-based PathAI, an acquisition by the Swiss…
Capricor Therapeutics accuses Nippon Shinyaku of slow-walking Duchenne drug
Capricor Therapeutics accused Nippon Shinyaku and its U.S. subsidiary of failing to follow through on marketing plans for…
3 Stocks Poised to Disrupt the Healthcare Market by 2030
The biggest mistake investors make with healthcare stocks is assuming the future will look like the past: incremental…